Biotectix Introduces a New Conductive Coating Designed for Medical Devices That Target Cardiac and Nervous System Applications
January 06 2015 - 8:00AM
Business Wire
- The coating, called Amplicoat™, is a
durable electro-conductive coating that is available for license
and commercialization on medical devices through
Biotectix.
- Amplicoat is designed to maximize
efficient and safe function of medical devices for the heart and
nervous system.
- Amplicoat enables next-generation
medical technology by making possible smaller, less invasive and
highly targeted devices.
Biotectix, a developer of conductive coatings for medical
devices that aim to optimize the communication between devices and
physiologic systems, today introduced a highly durable
electro-conductive polymer coating.
The new coating, called Amplicoat™, incorporates
Photolink®, a proprietary surface modification technology developed
by Eden Prairie, MN-based SurModics, Inc. (NASDAQ: SRDX). Designed
to enhance communication at the interface between human tissue and
a medical device’s electrode, Amplicoat overcomes the limitations
of other conductive coatings, including poor durability, difficult
processing requirements, and limited performance. The new coating
can be easily applied to a variety of metal electrodes, providing
an optimal solution for numerous medical-device applications,
including neurostimulation, cardiac pacing, electrophysiology
recordings, cochlear implants, and gastrointestinal recording and
stimulation.
“Amplicoat is a true breakthrough technology that provides a
durable electrode coating that conducts both ionically and
electronically, resulting in lower impedance and an expanded range
for safe charge delivery,“ said Dr. Sarah Richardson-Burns, who
co-founded Biotectix with Jeff Hendricks, PhD.
Amplicoat enables device electrode miniaturization, offering
higher numbers of electrodes for a given-sized lead or device and
providing greater tissue-sensing resolution as well as more
localized stimulation control. The coating enables higher signal
fidelity, lower power requirements, and reduced stimulation
thresholds.
“I am very proud of the Biotectix team. The dedication and
knowledge needed to commercialize this technology was significant,”
said Omar Amirana, MD, Biotectix Chief Executive Officer and Senior
Vice President of Allied Minds (LSE: ALM), the parent company of
Biotectix.
Biotectix is currently working with customers to incorporate
Amplicoat into their medical devices. In addition, there are
non-medical applications for conductive coatings, which are
currently under development at Biotectix.
About Biotectix, LLC.
Biotectix develops electro-conductive coatings technology for
medical devices and non-medical applications. The company, based in
Ann Arbor, Michigan, was formed in 2007 through a joint venture
between the University of Michigan, Ann Arbor and Allied Minds.
More information can be found on www.biotectix.com.
About Allied Minds
Allied Minds (LSE: ALM) is an innovative U.S. science and
technology development and commercialization company. Operating
since 2006, Allied Minds forms, funds, manages and builds products
and businesses based on innovative technologies developed at
leading U.S. universities and federal research institutions. Allied
Minds serves as a diversified holding company that supports its
businesses and product development with capital, central management
and shared services. More information about the Boston-based
company can be found at www.alliedminds.com.
Allied Minds Forward-Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company’s future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risk and uncertainties described in the risk factors
included in the company’s regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law, regulatory requirement, the Listing Rules and the
Disclosure and Transparency Rules, neither the company nor any
other party intends to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
PhotoLink® is a registered trademark of SurModics, Inc.
Media Contact:ArcPoint Strategic CommunicationsChristine
Dunn, 617-484-1660, x101cdunn@arcpointstrategy.com
Allied Minds (LSE:ALM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allied Minds (LSE:ALM)
Historical Stock Chart
From Apr 2023 to Apr 2024